Will Johnson & Johnson Raise Its Dividend in 2018?
Just about everyone has some products from Johnson & Johnson (NYSE: JNJ) in their medicine cabinets, ranging from over-the-counter medicines like Tylenol and Benadryl to Band-Aid bandages. Yet what has driven Johnson & Johnson's growth lately -- both in its overall sales and in the dividends it pays to its shareholders -- has been the healthcare giant's pharmaceutical business.
With decades of dividend growth under its belt, Johnson & Johnson has given its investors reason to expect regular dividend increases each and every year. But are there any challenges that J&J faces right now that could jeopardize that long streak of rising payouts in 2018? Let's take a closer look to see what dividend investors should look for from Johnson & Johnson in the year to come.
Image source: Johnson & Johnson.
Source: Fool.com
Johnson & Johnson Aktie
Mit 41 Buy-Einschätzungen und nur 1 Sell-Einschätzungen ist Johnson & Johnson einer der Lieblinge unserere Community.
Das Kursziel von 196 € für Johnson & Johnson weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 143.98 € hin.
